trending Market Intelligence /marketintelligence/en/news-insights/trending/_sf8rprqwoabjfql8ucxqg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Stealth BioTherapeutics plans Hong Kong IPO

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Report: Stealth BioTherapeutics plans Hong Kong IPO

Stealth BioTherapeutics Inc. intends to launch an IPO in Hong Kong as soon as 2018, Bloomberg News reported, citing people with knowledge of the matter.

The Newton, Mass.-based biotechnology company — which develops therapies for diseases involving dysfunction of the mitochondria, the cell structure which creates energy — could aim to raise about $200 million, according to Bloomberg's sources. The company has tapped advisers for the proposed transaction, whose preparations are at an early stage.

Stealth's IPO proposal comes as Hong Kong Exchanges & Clearing Ltd., the parent company of the city's stock exchange, expands its listing regime to cover specific criteria for qualified biotech companies that have yet to generate revenue or profit. Ascletis Inc. was the first biotech company to lodge an application under the new listing rules, according to the report.

Menlo Park, Calif.-based startup Grail Inc. — which develops a blood screening test for early cancer detection and whose investors include Microsoft Corp. co-founder Bill Gates — and China's Shanghai Henlius Biotech Co. Ltd. — which develops monoclonal antibody drugs and is backed by Fosun International Ltd. — are both planning to float in Hong Kong, people familiar with the matter told Bloomberg.